Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei.
Burkholderia pseudomallei, the causative agent of melioidosis, is intrinsically resistant to a wide range of antimicrobial agents including beta-lactams, aminoglycosides, macrolides, and polymyxins. We used Tn5-OT182 to mutagenize B. pseudomallei to identify the genes involved in aminoglycoside resistance. We report here on the identification of AmrAB-OprA, a multidrug efflux system in B. pseudomallei which is specific for both aminoglycoside and macrolide antibiotics. We isolated two transposon mutants, RM101 and RM102, which had 8- to 128-fold increases in their susceptibilities to the aminoglycosides streptomycin, gentamicin, neomycin, tobramycin, kanamycin, and spectinomycin. In addition, both mutants, in contrast to the parent, were susceptible to the macrolides erythromycin and clarithromycin but not to the lincosamide clindamycin. Sequencing of the DNA flanking the transposon insertions revealed a putative operon consisting of a resistance, nodulation, division-type transporter, a membrane fusion protein, an outer membrane protein, and a divergently transcribed regulatorprotein. Consistent with the presence of an efflux system, both mutants accumulated [3H] dihydro streptomycin, whereas the parent strain did not. We constructed an amr deletion strain, B. pseudomallei DD503, which was hypersusceptible to aminoglycosides and macrolides and which was used successfully in allelic exchange experiments. These results suggest that an efflux system is a major contributor to the inherent high-level aminoglycoside and macrolide resistance found in B. pseudomallei.
Moore
R A
RA
Department of Microbiology and Infectious Diseases, University of Calgary Health Sciences Centre, Alberta, Canada.
DeShazer
D
D
Reckseidler
S
S
Weissman
A
A
Woods
D E
DE
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000494:pharmacology*; D016957:Burkholderia pseudomallei / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism / Q000472:pathogenicity; D015169:Colony Count, Microbial; D006224:Cricetinae; D004251:DNA Transposable Elements / Q000235:genetics; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D005816:Genetic Complementation Test; D007763:Lac Operon; D007928:Lethal Dose 50; D018942:Macrolides; D008554:Melioidosis / Q000188:drug therapy / Q000382:microbiology; D008647:Mesocricetus; D009154:Mutation; D010957:Plasmids; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017384:Sequence Deletion; D013307:Streptomycin / Q000378:metabolism; D014774:Virulence; D001616:beta-Galactosidase / Q000378:metabolism
D000900:Anti-Bacterial Agents; D004251:DNA Transposable Elements; D018942:Macrolides; D001616:beta-Galactosidase; D013307:Streptomycin